October 31, 2016 - The court granted defendants' motion to dismiss with prejudice.
February 1, 2016 - Defendants filed a motion to dismiss.

December 1, 2015 - The lead plaintiff filed an amended complaint on behalf of investors who purchased CorMedix Inc (NYSEMKT: CRMD) common shares between June 24, 2014 and June 29, 2015. The lead plaintiff alleges that the defendants violated the Securities Exchange Act of 1934 by issuing false and misleading statements between June 24, 2014 and June 29, 2015.

September 22, 2015 - Lead plaintiff and lead counsel were appointed.

September 4, 2015 - Lead plaintiff motions were filed.

July 7, 2015 - An investor in shares of CorMedix Inc (NYSEMKT: CRMD) filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by CorMedix Inc in connection with certain allegedly false and misleading statements made between March 12, 2011 and June 29, 2015.

According to the complaint the plaintiff alleges on behalf of purchasers of CorMedix Inc (NYSEMKT: CRMD) common shares between March 12, 2011 and June 29, 2015, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 12, 2011 and June 29, 2015 defendants made allegedly false and/or misleading statements and/or allegedly failed to disclose that: CorMedix Inc’s announcements regarding its partnership discussions and imminent Phase 3 trials for its sole product, Neutrolin, were materially false and misleading, that clinical studies touted by CorMedix Inc were misleading and overstated Neutrolin’s effectiveness when in fact Neutrolin offers no benefit compared to current industry protocols, that CorMedix Inc overstated the cost effectiveness of Neutrolin compared to currently established medical protocols, that CorMedix Inc’s market claims for Neutrolin were overstated, that CorMedix Inc stock achieved an unsustainable valuation by using paid stock promoters, yet failed to disclose the use of such promoters in its regulatory filings pursuant to Section 17(b) of the Securities Act of 1933, that CorMedix Inc insiders enriched themselves at the expense of shareholders by selling stock at inflated prices, and that as a result of the foregoing, CorMedix Inc’s public statements were materially false and misleading at all relevant times.

Shares of CorMedix Inc (NYSEMKT: CRMD) grew from $1.33 per share in December 2014 to as high as $9.87 per share in April 2015.

Then on June 29, 2015, a report was published on CorMedix Inc asserting, among other things, that CorMedix Inc is based on a 1970s-era catheter product acquired for less than $1 million in a bankruptcy sale, apparently after at least two failed sales processes, that CorMedix Inc’s market size claims are greatly exaggerated, and that CorMedix Inc is touting misleading clinical-data, as in-depth industry research shows its Neutrolin/Taurolidine product is a failure and “40% benefit!” versus industry standards is inaccurate.

Shares of CorMedix Inc (NYSEMKT: CRMD) declined on June 29, 2015, to as low as $3.62 per share., respectively $3.20 per share on July 2, 2015.